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Abstract: The coronavirus disease 2019 (COVID-19) pandemic, an infection caused by the severe acute
respiratory syndrome coronavirus (SARS-CoV-2), has led to more than 771,000 deaths worldwide.
Tobacco smoking is a major known risk factor for severe illness and even death from many respiratory
infections. The effects of smoking on COVID-19 are currently controversial. Here, we provide an
overview of the current knowledge on the effects of smoking on the clinical manifestations, disease
progression, inflammatory responses, immunopathogenesis, racial ethnic disparities, and incidence
of COVID-19. This review also documents future directions of smoking related research in COVID-19.
The current epidemiological finding suggests that active smoking is associated with an increased
severity of disease and death in hospitalized COVID-19 patients. Smoking can upregulate the
angiotensin-converting enzyme-2 (ACE-2) receptor utilized by SARS-CoV-2 to enter the host cell and
activate a ‘cytokine storm’ which can lead to worsen outcomes in COVID-19 patients. This receptor can
also act as a potential therapeutic target for COVID-19 and other infectious diseases. The COVID-19
pandemic sheds light on a legacy of inequalities regarding gender, racial, and ethnic health disparities
associated with active smoking, thus, smoking cessation may help in improving outcomes. In addition,
to flatten the COVID-19 curve, staying indoors, avoiding unnecessary social contact, and bolstering
the immune defense system by maintaining a healthy diet/living are highly desirable.
Keywords: COVID-19; ACE-2; SARS-CoV-2; α7-nAChR; smoking; vaping; e-cigarettes; hooka and
cytokine storm

1. Introduction
Recently, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak spread is
noticed across the world that is assumed to be originated from Wuhan, China. Figure 1 depicts a
graphical representation of top ten infectivity countries from 1st February to 1st August 2020 (data
derived from Worldometer, https://www.worldometers.info/coronavirus/). Coronaviruses are RNA
viruses which can be classified into four genera based on their genomic characteristics: α, β, π, and ξ [1].
Based on sequencing and evolutionary data, bats are the currently proposed source reservoir for
coronaviruses [2,3]. COVID-19 infections have a high homology (>80%) to severe acute respiratory
syndrome coronavirus (SARS-CoV), which was responsible for the acute respiratory distress syndrome
(ARDS) outbreak in Guandong Province in Southeast China in 2003. The World Health Organization
(WHO) declared that the COVID-19 outbreak is a pandemic on 11 March 2020 [4]. As of 16 August 2020,
the disease has spread to over 188 countries and territories around the world and has caused more than
Int. J. Mol. Sci. 2020, 21, 6581; doi:10.3390/ijms21186581
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The latest finding suggests that patients with a greater number of comorbidities experienced a
greater disease severity from COVID-19 compared to healthy patients without underlying medical
conditions [10]. Similar to avian influenza H7N9 virus and SARS-CoV infections, SARS-CoV-2 is
more readily predisposed to cause respiratory failure and death in susceptible patients associated
Int. J. comorbidity
Mol. Sci. 2020, 21,
6581 including hypertension, diabetes, cancer, and cardiovascular diseases2[10–
of 22
with
factors,
14]. Every year, more than 8 million deaths are associated to tobacco consumption globally [15].
Smokers
are cases,
knownresulting
to experience
more
complications
than non-smokers,
as for
evident
by
21.4 million
in more
thanrespiratory
771,000 deaths
[5,6]. Furthermore,
the Centers
Disease
multiple
studies
showing
that
smokers
experience
increased
rates
of
influenza,
bacterial
pneumonia,
Control and Prevention (CDC) has stated that not all COVID-19 infections are fatal, and an estimated
and
tuberculosis
[16–18].
As mentioned
in previous
studies,ofpatients
with from
chronic
obstructive
that 40%
of patients
are asymptomatic;
however
the possibility
transmission
people
with no
pulmonary
disease
(COPD)
are
more
susceptible
for
viral
infections
and
presented
worse
outcomes
symptoms is 75% and more than 14 million people have been recovered [7,8]. According to WHO
and
[19,20].
Notably,
patients
pre-existing
and current
tobacco
use are much
moreproduced
likely to
CDC, the
COVID-19
viruswith
typically
spreadsCOPD
from person
to person
by respiratory
droplets
experience
poor therapeutic
from
COVID-19
[21,22].
Early evidence
shows that
patients
during coughing,
sneezing oroutcome
talking and
enters
the body
via mucosal
tissues, including
thein
nasal,
oral,
who
have
a
history
of
smoking,
the
risk
of
adverse
health
outcomes
for
patients
with
COVID-19
upper respiratory tract, and less frequently through the conjunctival mucosa [9]. Furthermore, common
increases
compared
to non-smokers,
is associated
with
higher
rates of
admission
to
symptomsdramatically
include fever,
cough, fatigue,
loss of theand
sense
of smell and
taste,
headache,
loss
of appetite,
intensive
care
units
(ICU),
of ventilators,
and leading
to death(s)
[23,24].
muscle and
joint
pain,
soreuse
throat,
vomiting, blood
coughing,
diarrhea,
and rash [9].

Figure 1.
1. Reported
Reported confirmed
confirmed COVID-19
COVID-19 cases
cases over
over time
time in
in top
top ten highly infected countries. Data
Data
Figure
accessed
on
15
August
2020,
using
Worldometer,
https://www.worldometers.info/coronavirus/.
accessed on 15th August 2020, using Worldometer, https://www.worldometers.info/coronavirus/.

The latest
finding
that
patients
with a greater
numberdue
of comorbidities
Since
smoking
is asuggests
major risk
factor
for respiratory
infections
to suppressiveexperienced
effect of thea
greater
disease
severity
from
COVID-19
compared
to
healthy
patients
without
underlying
medical
immune response, thus a hypothetical link between smoking and worsening COVID-19 can be
made
conditions
[10].
Similar
to
avian
influenza
H7N9
virus
and
SARS-CoV
infections,
SARS-CoV-2
is
more
[25,26]. Smoking is a well-established risk factor in lung cancer, COPD, and asthma [27], which
in
readily
predisposed
to
cause
respiratory
failure
and
death
in
susceptible
patients
associated
with
turn have been shown to be risk factors for more severe illness in COVID-19 patients [28]. To reduce
comorbidity
including
cancer, and cardiovascular
[10–14].
the
incidencefactors,
and severity
of hypertension,
an infectious diabetes,
disease, understanding
the impact diseases
of host factors,
Every year, avoidable
more thanlifestyle
8 million
deaths
to tobacco
consumption
globally
[15].
particularly
factors
suchare
as associated
smoking, may
play a vital
role. Based
on recent
Smokers are known to experience more respiratory complications than non-smokers, as evident
by multiple studies showing that smokers experience increased rates of influenza, bacterial
pneumonia, and tuberculosis [16–18]. As mentioned in previous studies, patients with chronic
obstructive pulmonary disease (COPD) are more susceptible for viral infections and presented worse
outcomes [19,20]. Notably, patients with pre-existing COPD and current tobacco use are much more
likely to experience poor therapeutic outcome from COVID-19 [21,22]. Early evidence shows that
in patients who have a history of smoking, the risk of adverse health outcomes for patients with
COVID-19 increases dramatically compared to non-smokers, and is associated with higher rates of
admission to intensive care units (ICU), use of ventilators, and leading to death(s) [23,24].
Since smoking is a major risk factor for respiratory infections due to suppressive effect of the
immune response, thus a hypothetical link between smoking and worsening COVID-19 can be
made [25,26]. Smoking is a well-established risk factor in lung cancer, COPD, and asthma [27],
which in turn have been shown to be risk factors for more severe illness in COVID-19 patients [28].
To reduce the incidence and severity of an infectious disease, understanding the impact of host
factors, particularly avoidable lifestyle factors such as smoking, may play a vital role. Based on recent
literature, the WHO confirmed that smokers may experience severe complications from COVID-19
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than non-smokers [15]. Considering the complications resulting from smoking in patients with
viral infections, we attempted to highlight research focusing on the association between smoking
and COVID-19 outcomes, including disease severity, pathogenesis, potential molecular mechanisms,
and possible therapeutic interventions.
2. The Epidemiology of Smoking and COVID-19
During the COVID-19 pandemic, there is a quest whether smoking increases the risk of acquiring
respiratory infections or the biological influence of nicotine on the SAR-CoV-2 [29–31]. No strong
evidence exists that support an increased risk of COVID-19 in smokers [32]. However, several indirect
studies suggest that this population is at a higher risk for a more severe infection amongst hospitalized
patients as evident by increased admission rates into ICU, use of ventilators, and death as compared
to non-smokers.
Recent studies demonstrated that 1.4–18.5% of hospitalized COVID-19 adult patients were
smokers [32]. Two meta-analyses studies (from China) were released the prevalence of COVID-19 in
smoker patients. Emami et al. [33] identified 10 articles which covered 76,993 patients and highlighted
an overall smoking history of 7.63% of patients (95% confidence interval (CI) 3.83–12.43%) who were
infected with SARS-CoV-2. Another meta-analysis with 5,960 hospitalized COVID-19 patients data
suggest that current smoking pooled prevalence of 6.5% (1.4–12.6%) [34].
Several epidemiologic case-control and cohort studies show the strong relationship between
smoking and severity on COVID-19 disease and death. Zhao et al. [22] identified seven studies and
concluded that the risk of severe COVID-19 (Odds Ratio (OR) = 1.98; 95% CI:1.29–3.05) is nearly
doubled in smokers. Zheng et al. [35] analyzed the data from thirteen studies comprising 3027
patients and found that smokers had greater disease progression with COVID-19, (current smoking:
OR = 2.51; 95% CI: 1.39–3.32; p = 0.0006). Baskaran et al. [36] conducted a meta-analysis in 2019
which included 27 studies and 460,592 participants and found that active smokers (pooled OR = 2.17;
95% CI: 1.70–2.76), and ex-smokers (pooled OR = 1.49; 95% CI: 1.26–1.75) were more prone to develop
community-acquired pneumonia compared to patients who had never smoked. A recent meta-analysis
published by Patanavanich and Glantz which includes 19 peer-reviewed papers with data on smoking
and COVID disease progression (17 from China, 1 from Korea, and 1 from the US) concluded that
smoking is associated with more double the odds of disease progression in people with COVID-19
infections (OR = 1.91; 95% CI: 1.42–2.59; p = 0.001) [37]. Liu et al. [38] conducted a study in a population
of 78 patients with COVID-19 and found a statistically significant association between smoking and
COVID-19 severity (OR = 14.28; 95% CI: 1.58–25.00; p = 0.018). Yu et al. [39] who reported on a study of
70 patients, a statistically significant (OR = 16.1; 95% CI: 1.3–204.2) in a multivariate analysis examining
the association between smoking and the exacerbation of pneumonia after treatment.
In contrast, several other studies could not find statistically significant link between smoking and
COVID-19 severity. Chen et al. [40] conducted a single center retrospective observational study in
Taizhou, Zhejiang, China which included 145 patients with COVID-19. This study concluded that the
more severely ill patients had a lower history of smoking when compared to less severely ill patients
(7.0% vs. 11.8%, p = 0.57). In a recent study, Dong et al. [41] analyzed data from 11 patients with
COVID-19 and concluded that there was a non-significant relationship between smoking and severity
of COVID-19. More findings by Kim et al. [42] in a recent Korean cohort study with 28 hospitalized
patients with confirmed COVID-19 in which only 5 of the patients out of 27 (18.5%) had any smoking
history. Another study by Zheng et al. [43] reported that only 10.9% of all patients in the study were
smokers, but 6.7% were smokers in the severe/critically ill group, which is not significantly (χ2 = 0.962,
p > 0.05) lower than of the ordinary group with 14.0%. They further concluded that no evidence exists
that smoking protects COVID-19 patients from developing to severe disease. Furthermore, another
study comprising 140 patients infected with SARS-CoV-2 in Wuhan, China, showed that only 9 (6.4%)
patients had a history of smoking, and 7 of them were past smokers, which suggests that smoking
history may not be a risk factor for COVID-19 disease severity [44].
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The incomplete patient health histories may impact the significance of hospital-based studies [44].
In an emergency context, smoking history collection is challenging and the severity of the disease
is often unclear and inconsistent throughout studies at different institutions and likely to lead to
significant sampling bias [44,45]. Characteristics of hospitalized patients can also vary based on
the services accessible, admission to clinics, treatment procedures, and likely other considerations
not included in the studies. Further, most study analyses are based on unadjusted ORs that were
either reported in the studies or calculated to account for age and other confounding factors [24,37].
Some peer-reviewed meta-analyses investigating the association between smoking and COVID-19
were also based on unadjusted ORs, but with few studies included [22,35,46,47]. All these evidences
support that smoking leads to greater morbidity and mortality in COVID-19 patients.
3. Smoking Modulates ACE-2 in COVID-19
The entry of coronavirus into human cells is a multi-step process involving various distinct
domains in spike (S) protein, that mediates viral attachment to the cell surface, receptor engagement,
protease processing, and membrane fusion [48]. Previous studies have reported that the S protein
binding to human cells was facilitated by ACE-2 receptor in several viruses, including NL63, SARS-CoV,
and now SARS-CoV-2 causing COVID-19 [49–53]. Through biophysical assays, Wrapp et al. [54]
confirmed that the modified S protein of SARS-CoV-2 has a 10- to 20-fold higher affinity for the ACE-2
receptor than SARS-CoV, which results in a more rapid spreading of SARS-CoV-2. Cigarette smoke has
been associated with an increased ACE-2 expression in type-2 pneumocytes and alveolar macrophages,
particularly at the apical end of the small airway epithelium as compared to non-smokers including
current COVID-19 patients, although the mechanism for this is not clear [55–57]. The binding of the
virus to ACE-2 cell surface proteins shields it against immune surveillance systems, keeping it attached
to the host cell for comparatively longer times, rendering it an effective carrier and prone host for
potential infections and further spread. Furthermore, the subsequent engulfment of ACE-2 provides
the virus with entry into the host cells network, thereby not only surviving and proliferating but also
mutating and altering processes of host evasion. Previous research has indicated that SARS-CoV-2
adhesion on ACE-2 could actually downregulate ACE-2 expression, which leads to an enhanced
secretion and activation of enzymes associated with ACE-2 [58]. Moreover, this variability and
the dramatic reduction in ACE-2 contribute to severe acute respiratory failure [59]. Several other
investigators have reported that smoking is associated with ACE-2 in COVID-19 which induces ACE-2
receptor mediated viral entry [60,61]. Furthermore, in vitro studies indicate that the SARS-CoV can
be modulated by a number of proteases such as furin, cathepsin L, and trypsin-like serine proteases
including transmembrane serine protease 2 (TMPRSS2), TMPRSS11A, and TMPRSS11D [62,63]. It has
been reported that TMPRSS2 and furin play essential roles in proteolytic activation of a broad
range of viruses including SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV),
and SARS-CoV-2 [60–62,64,65]. In addition, it has been shown that S protein priming and cell membrane
fusion of SARS-CoV-2 is induced by S protein furin cleavage site putative furin recognition motif
(PRRARSV) and TMPRSS2 cleavage site (S1/S2 R682/683/685 and S2 R815) [66–68]. In addition, the furin
site at the SARS-CoV-2 S1/S2 boundary is unique and essential to highly efficient S protein cleavage
and a key determinant of the transmissibility and pathogenicity of the virus [65,66,69]. Interestingly,
expression of the TMPRSS2 is upregulated in the small airway epithelium of smokers as compared to
non-smoker, but not other proteases TMPRSS11A and TMPRSS11D [70]. Studies have also shown that
smoking can lead to increases in androgen hormones, such as testosterone. Moreover, the androgen
receptor has been found to increase the expression of TMPRSS2 [71].
Nicotine is known to have an effect on the renin-angiotensin system (RAS) by
up-regulating the receptor axis, ACE/angiotensin (ANG)-II/ANG II type 1 and down-regulating
the ACE-2/ANG-(1–7)/Mas receptor axis, which may in turn contribute to cardio-pulmonary
pathologies [72]. In a recent editorial, it has been proposed that the nicotinic cholinergic system
could be implicated in COVID-19 infection because COVID-19 clinical manifestations such as a
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recent study, COVID-19 ICU patients suffered higher systemic inflammatory response due to
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which eventually damages the lung architecture contributing to further additional severe complications.
Smoking increases the severity of COVID-19 associated inflammatory response. In a recent study,
COVID-19 ICU patients suffered higher systemic inflammatory response due to increased plasma levels
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IL2, IL7, IL10, granulocyte colony-stimulating factor (GC-SF), interferon-gamma (IFN-γ)-inducible
protein (IP10, CXCL10), MCP1, macrophage inflammatory protein 1 alpha (MIP1A), and TNF-α [79].
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW
6 of 22
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leading to the excessive production of pro-inflammatory cytokines and chemokines including IL-2,7,
10, TNF-α, GS-CF, macrophage inflammatory protein 1α (MIP1α), MIP1β and MCP1. These proteins
attract other immune cells and promoting further inflammation which establishes a cytokines storm.
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5. Impact of Active and Passive Smoking on COVID-19
The COVID-19 pandemic continues to evolve and poses a global threat to identify prognostic
factors. Among the epidemiological risk factors, the role of concurrent smoking as a risk factor
for COVID-19 associated pneumonia is controversial. Leung et al. [60] noted the association of
higher ACE-2 expression with COPD and current smokers with putatively important implications
for COVID-19 patients. Additionally, current smokers showed a higher ACE-2 gene expression as
compared to non-smokers and hypothesized that the elevated ACE-2 expression in smokers might
predispose them to an increased risk of SARS-CoV-2 infections [60].
In contrast, more recent studies by Rossato et al. [90] and others revealed that COVID-19 patients
had a very low prevalence of smoking, with no major connection between active smoking and fatal
disease in COVID-19 patients [33,45,91]. These findings resemble with the China’s COVID-19 clinical
reports [10,33,45,47]. However, Leung et al. [60] and others concluded that smoking was a significant
risk factor for COVID-19 associated pneumonia, in comparison to consolidated epidemiological
data from China [10,45,47]. Interestingly, Guan et al. [45] concluded that no significant association
exists between current smoking and severe disease in COVID-19 patients because they excluded a
sensitivity analysis (a sensitivity test to see the impact of a single study on the smoking and COVID-19).
However, in an updated meta-analysis by Fei Ran Guo [92] it was determined that smoking links
to the severity of COVID-19 when this same sensitivity test was applied. Furthermore, Lippi and
Henry meta-analysis has demonstrated that there is no link between smoking status and COVID-19
severity [47]. In addition, meta-analysis by Vardavas and Nikitara [23] included five studies and
concluded non-significant relationship between smoking and severity of COVID-19. More findings
by Hu et al. [93] showed that smoking are associated with unfavorable clinical outcomes of disease
(OR = 3.464; 95% CI: 1.18–10.166; p = 0.001). Moreover, Ernest Loa and Benoit Lasnier [94] state that
the meta-analysis by Lippi and Henry had an erroneously interpreted their results due to the use of
null hypothesis significance testing (NHST) approach which is known to have major limitations as
discussed in recent high-profile statements [95,96]. Leng et al. [46] also published a report regarding
Lippi and Henry’s meta-analysis data, in which he attempts to explain the reason behind their
conclusion. The misclassification of smoking due to underreporting in these cohorts may be an
explanation. The other possible reason might be that “smokers may be taking medications that may
offer some protection against COVID-19 [46]. As noted previously, COVID-19 more strongly affects the
older population (>65 years) with co-morbidities, while smoking rates in this age bracket are around
3–5 times lower than in the general population. As a result, in the COVID-19 susceptible subgroups,
the baseline smoking rates may also be significantly lower than the general smoking rates of the
population [46]. Therefore, we should be especially careful about the messages surrounding smoking
and COVID-19, particularly in these fraught times where misinformation is commonly amplified in a
vacuum of rigorous evidence [97,98].
6. Electronic Cigarette, Vaping, Hooka and COVID-19
The role of smoking in COVID-19 raises a question of whether this is also relates to individuals
interested with water pipe smoking and those switching over to electronic cigarettes and “I Quit
Original Smoking” (IQOS) devices colloquially referred to as “heat-not-burn” devices in which tobacco
products are heated up using a battery-powered heating system, with the supposed advantage of
reducing the number of harmful chemicals released [99]. Currently, there is little direct evidence
showing the effect of e-cigarette use on COVID-19 outcomes. Certain news outlets have started
speculating on links between e-cigarettes and worsening COVID-19, primarily based on evidence
suggesting that e-cigarettes use leads to lung damage and also that persons with lung problems
have more severe symptoms, then e-cigarettes thought to lead to worse outcomes for COVID-19
patients [100].
A recent study demonstrated that mice exposed to e-cigarette smoke/vaping had more
complications from influenza than non-vaping mice [101]. Vaping may have impaired immune
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responses in mice, but it is not clear whether the study results can be applied to humans and COVID-19
patients [101]. Clinical trials and other studies have demonstrated that these devices are not “safer”,
and have caused damage to the airways epithelial and as well as a considerable reductions in
transcutaneous oxygen tension in young tobacco smokers, and short-term impaired arterial oxygen
tension in heavy smokers [102–105]. Due to their design, these products are brought to the mouth and
face to inhale repeatedly, and many users have an increased urge to cough or expectorate which can
increase the transmission of COVID-19. In addition, the aerosols and vapors generated by electronic
substance delivery systems could contribute to SARS-CoV-2 transmission [106].
Another way of smoking is a hookah (shisha or waterpipe), a single- or multi-stemmed instrument
typically used by multiple people simultaneously. In the United States (US), “hookah bars” have gained
popularity in recent years with nearly 2.6 million people smoking hookah products and there also an
estimated 100 million hookah users worldwide [107–109]. By virtue of their design, hookahs are ideal
vectors for viral spreading and may escalate the risk for more severe COVID-19 infections through
public use, complex cleaning requirements, and a cold-water reservoir, suitable for SARS-CoV-2
transmission [109]. In addition, hookah smoke contains some harmful chemicals that can damage the
respiratory lining and predispose smokers to respiratory infection such as MERS-CoV [110].
Due to the risks of public health posed by transmission of SARS-CoV-2, some countries have
already imposed restrictions on hooka use [111]. The usage of e-cigarettes and hookah/waterpipe
smoking should be stopped during the SARS-CoV-2 transmission cycle or at least from the start of
symptoms. Additional research into these products and their influence on the virulence of COVID-19
is still needed.
7. Smoking in Sex Predisposition and Racial Ethnicity in COVID-19
The COVID-19 pandemic has exposed longstanding racial and ethnic health-related disparities,
largely driven by socio-economic and environmental factors [112]. COVID-19 epidemiological studies
also showed sex-specific differences in incidence and fatality rates with a higher rate in males (2.8%)
compared to females (1.7%) also associated with smoking [113–115]. In a recent study [115], differences
in COVID-19 disease prevalence and severity were associated with sex and smoking. Smoking is
associated with ACE-2 which have alleles that offer COVID-19 resistance and clarify a lower rate of
mortality for women since they are located on the X chromosome [115].
The sex hormones (testosterone and estrogen) have shown distinct effects on immune function,
which can affect immune defense or disease severity. There is also a clear sex-dependent incidence of
this disease, with a higher incidence in men than in women, which may be due to the higher rate of
smoking among men. Several recent studies indicate that estrogens appear to upregulate ACE-2 in
younger children and adult women. This seems to lead to a higher level of ACE-2 than in older adults
that could explain the milder COVID-19 in women and children and suggest a protective effect [116,117].
The expression of ACE-2 was more prevalent in Asian men, which could explain the higher prevalence
of COVID-19 in this group of patients than in women and patients of other ethnicities [118]. Several
studies suggest that there could be a sex predisposition to COVID-19, with men more likely to be
affected [44,45,119]. One study found that the distribution was equal between sexes as determined in
a cohort of 140 patients in China with COVID-19 [44]. Another study report that more males (67%)
were diagnosed as critically ill [119]. In a recent study by Guan et al. [45] which included 552 hospitals
across 30 provinces in China with 1099 COVID-19 patients, 58% were men. This sex predisposition can
be correlated with the significantly higher incidence of smoking among men than women in China.
Cai et al. [55] reported that no significant differences were found in the expression of ACE-2 between
Asians and White patients, or male and female or older and younger than 60 years. Interestingly, its
expression was considerably higher in current Asian ethnic smokers than in Asian non-smokers, but no
disparities between White smokers and non-smokers were recorded. However, existing research does
not endorse smoking as a predisposing factor for SARS-CoV-2 infection in men or any subgroup. In a
recent study from Zhang et al. [44] only 1.4% of patients were current smokers; similar results were
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indicated in the study by Guan et al., showing only 12.6% of patients as current smokers [120]. In both
studies, comparatively low numbers of active smokers are unlikely to be correlated with the prevalence
or severity of COVID-19 as compared to the ratio of male smokers in China (50.5%).
Without stronger evidence of the association between the predominance or severity of COVID-19
in Asian men compared to other subgroups, no firm conclusions can be drawn. ACE-2 expression
variability can be further studied in more cases from diverse ethnic and genetic backgrounds globally
in order to see whether it leads to altered COVID-19 susceptibility in various subgroups.
There are also variations in lifestyle and diseases, mental and physical, through ethnic groups
which may clarify the vulnerability to a severe COVID-19 infection [121]. Several co-morbidity factors
are suspected to contribute to the disproportionate impact of COVID-19 among African Americans,
including high rates of underlying health conditions like cardio-pulmonary diseases and diabetes,
which increases the risk of a more severe illness from COVID-19. As mentioned in one study, smoking
is a major cause of these underlying conditions, and African Americans experience higher rates of
many chronic conditions linked to COVID-19 and 18.3% of African American adults are current
smokers [122]. Smoking among African American men is higher than among African American women
(21.8% vs. 15.4%) and this population group is more likely to be exposed to second-hand smoke than
any other racial or ethnic group. Moreover, mostly African American dominated US counties have
a three-fold higher infection rate and a six-fold higher mortality risk than other White dominated
counties [123].
8. Does Cessation of Tobacco Consumption Lead to Lower COVID-19 Risk?
Studies show that smokers are more prone to developing COVID-19 and more vulnerable to
severe COVID-19 complications. A crucial question both to determine causality and to provide advice
and effective interventions to patients is whether the risk of developing a tobacco-associated COVID-19
infection can be reduced after quitting smoking. Unfortunately, there are limited existing data on the
impact of smoking cessation during the COVID-19 pandemic. Research data suggest that up to 70%
of smokers have an interest in stopping smoking, but only 3–10% can do so on their own [124,125].
Smoking cessation before surgery leads to a rapid reduction in nicotine and carboxyhemoglobin a
level in the bloodstream, which also provides smokers an opportunity to engage in long-term smoking
cessation [126,127]. Smoking withdrawal for 4 weeks or longer has evidence of a decreased risk
for COVID-19 and a lower risk of more severe complications. A recent study by Turan et al. [128]
examining 635,265 non-cardiac surgical patients noted that current smokers had a higher likelihood
of 30-day mortality (RR = 1.38; 95% CI: 1.11–1.72) and serious post-operative complications such
as surgical site infection (OR = 1.30; 95% CI: 1.80–2.43), unplanned intubation (OR = 1.87; 95% CI:
1.58–2.21), pneumonia (OR = 2.09; 95% CI: 1.80–2.43), and septic shock(OR = 1.55; 95% CI: 1.29–1.87).
In other meta-analysis by Wong et al. [129] that included 25 studies on short term preoperative smoking
cessation and post-operative complications, it was found that a minimum of 4-weeks of smoking
cessation before surgery lowered the risk of respiratory complications and that cessation of at least
three to four weeks also reduced wound-healing complications when compared to current smokers.
Findings also suggest that the serum half-lives of carbon monoxide and nicotine are approximately
4 h and 1 h, respectively [127]. Another study reported that an average carboxyhemoglobin serum
level in smokers is 3.81 ± 2.17 g/dL−1 as compared to 2.95 ± 1.33 g/dL−1 in non-smokers [130].
It is plausible that an increase in cessation rates could help minimize community transmission
of SARS-CoV-2. Evidence shows that various strategies incorporating both pharmacological and
behavioral interventions during viral epidemics are better positioned to reduce smoking-related
complications by encouraging cessation [131]. Healthcare providers should be involved in offering
evidence-based pharmacological and behavioral smoking cessation interventions by remote support
if in-person visits are not possible. A recent study shows that varenicline is the most effective
smoking cessation pharmacotherapy followed by bupropion and nicotine patches [132]. In a
12-week double-blind, randomized, placebo-controlled clinical trial study of 8144 participants,
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varenicline improved higher abstinence rates compared with placebo (OR = 3.61; 95% CI: 3.07–4.24),
nicotine patch (OR = 1.68; 95% CI: 1.46–1.93), and bupropion (OR = 1.75; 95% CI 1.52–2.01) [132].
Furthermore, bupropion and nicotine patch showed a trend toward higher smoking cessations rates as
compared to placebo (OR = 2.07; CI: 1.75–2.45 and OR = 2.15; 95% CI: 1.82–2.54, respectively) [132].
Telemedicine can be employed by doctors to advise smokers about the benefits of smoking cessation.
Long-term lockdowns will contribute to and increase the frequency of social distancing, and may
exacerbate or even cause mental disorders, which can increase the urge to smoke; within these socially
deprived populations, smoking becomes more common, which increases the risk of this population
contracting COVID-19. Cessation of smoking is expected to reduce the risk of COVID-19 emerging
and severe COVID-19 complications.
9. Could Nicotine Be a Therapeutic Option to Lower COVID-19 Risk?
Nicotine is a cholinergic anti-inflammatory agonist that regulates the immune and inflammatory
responses of the host [133–136]. Farsalinos et al. [34] claim that pharmaceutical nicotine should
be considered a viable therapeutic option for COVID-19. Changeux et al. [137] have proposed the
“nicotinic hypothesis,” where nicotinic acetylcholine receptors may be a potential therapeutic target
to reduce SARS-CoV-2 infections and alleviate COVID-19 disease. Previous studies have reported
that medicinal nicotine has been used successfully for tobacco addiction and has been tested for,
the treatment of neurological disorders in non-smokers [138]. Nicotine also prevented acute lung
injury in an animal model of ARDS, inhibited TNF-α expression in airway epithelial cells in vitro
and exhibited anti-inflammatory properties in vivo in humans exposed to endotoxins [139–141].
Several studies have also reported that nicotine inhibits the production of pro-inflammatory cytokines
(TNF-α, IL-1, and IL-6), without inhibiting the production of anti-inflammatory cytokines such as
IL-10 [133,142,143]. These effects have been shown to protect against cytokine-mediated diseases such
as sepsis and endotoxemia, which can lead to organ damage or even death as from a ‘cytokine storm’,
the main culprit in COVID-19 [81,144–146]. Since expression of IL-6 has been considered a predictor
of mortality, it also act as a pharmacological target, tocilizumab (TCZ) has already been studied in
clinical trials in an effort to treat patients with severe COVID-19 by neutralizing these key inflammatory
mediators [87,144,146–149].
Furthermore, smoking and nicotine-induced downregulation of ACE-2 was identified prior to
the COVID-19 pandemic [72,150]. However, more recent findings indicate that ACE-2 is upregulated
in this disease [57,60,120]. This recently identified upregulation of ACE-2 is presumably a protective
mechanism against tissue damage caused by SARS-CoV-2. ACE-2 has been previously identified
to protect mice from developing ARDS [59,151,152]. Based on previous SARS research evidence,
SARS-CoV-2 capable to induce an abrupt reduction in ACE-2, which is thought to be related to increased
morbidity and tissue damage [153]. Therefore, ACE-2 upregulation, while apparently paradoxical,
will potentially defend patients from severe disease and lung injury [154].
However, these results do not definitively answer the questions surrounding the effects
of nicotine or smoking on ACE-2. They can also show the complex equilibrium between
angiotensin-converting-enzyme (ACE) and ACE-2, which can shift constantly based on stressors
and triggers. Recent study report that local or systemic infection may lead acute lung injury and
vasoconstriction via involvement of ACE, angiotensin I and II system in various respiratory diseases
including COVID-19. In the same process, ACE-2 has relation with group of angiotensin as a regulatory
enzyme which convert the angiotensin II to angiotensin-(1–7) and have role in modification of
angiotensin II into angiotensin-(1–9). This regulation will be attenuating the effects on vasoconstriction,
sodium retention, and fibrosis induced by angiotensin [153,155]. There is still some uncertainty
about how nicotine affects the progression COVID-19 via the renin-angiotensin-aldosterone axis and
how ACE-2 and α7-nAChR receptors interact. More concrete evidence is required before medicinal
nicotine can be recommended for COVID-19. It is critical to distinguish between cigarette smoking
and medicinal nicotine for the prevention and treatment of COVID-19, because smoking cannot play
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impede viral RNA synthesis. Remdesivir (GS-5734), is a phosphoramidate prodrug of an adenine
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derivative, and which was used in treatments against Ebola, SARS-CoV, and MERS-CoV, as it has
the potential to outcompete the proofreading ability of coronavirus exonuclease, and carries a high
genetic resistance barrier [36,43,45,101]. Recent in vitro studies have shown that remdesivir effectively
inhibits SARS-CoV-2 (EC50 in Vero E6 cells = 0.77 µM [11,156]. Earlier studies implied that remdesivir
exhibited broad-spectrum activity against SARS-CoV-2 and similar viruses (including SARS-CoV and
MERS-CoV) [156,168].
Favipiravir (T-705), is a nucleoside analogue that inhibits RdRp of RNA viruses, such as influenza
virus, Ebola virus, flavivirus, chikungunya virus, norovirus, and enterovirus [169]. Another recent
study has shown that Favipiravir (EC50 in Vero E6 cells = 61.88 µM) against SARS-CoV-2 and blocked
viral infection [156]. A clinical study of favipiravir has shown a promising clinical efficacy in treating
SARS-CoV-2 and its possibility to be safely included in future treatment plans, as it has shown both
efficacy and bio-availability of the drug [170].
In addition, ribavirin and azvudine have shown some promising in vitro results for their efficacy
against SARS-CoV-2, and it’s in vivo efficacy is currently being tested in three ongoing clinical
trials [171,172].
Chloroquine and hydroxychloroquine are currently licensed for malaria, and autoimmune
diseases such as lupus, blood disorder porphyria cutanea, rheumatoid arthritis and many countries
have extensively used for COVID-19 treatment [173,174]. Researchers have found that Chloroquine
and hydroxychloroquine have in vitro inhibitory effect against several viruses in including SARS-CoV
and SARS-CoV-2 [173,175]. Based on these results, chloroquine and hydroxychloroquine are
currently promoted for treatment of hospitalized COVID-19 patients in several countries [176].
A chloroquine-based drug was documented to inhibit SARS coronavirus fusion with the cells,
by acidifying lysosomes and thereby inhibiting pH-low cathersin to optimally cleavage the S protein
SARS-CoV-2 [175]. In addition, chloroquine has been shown to disrupt terminal ACE-2 glycosylation
in the Golgi system, thus inhibiting viral penetration into host cells [177]. However, neither
chloroquine nor hydroxychloroquine have been used in clinical setting to prevent COVID-19,
because their administration is associated with significant adverse effects, such as loss of vision,
nausea, stomach problems, and potential cardiovascular issues. Chloroquine and hydroxychloroquine
act by accumulating in lymphocytes and macrophages and by reducing the secretion of proinflammatory
cytokines, and/or by activating anti-SARS-CoV-2 CD8+T-cells [177]. These antimalarial agents have
shown in vitro efficacy, either alone or in combination with azithromycin, against SARS-CoV-2
according to the results of several recent studies [178,179]. However, these results have been challenged
by new trials with no substantial advantages from hydroxychloroquine administration even though
antimalaria drugs are being tested in more than 30 randomized controlled trials [172].
Virus-induced immune responses leading to cytokine storm syndrome and hyperinflammation
are associated with ARDS which can result in multiple organ dysfunction or death [149]
Immunosuppressants along with antivirals play a crucial role in counteracting severe SARS-CoV-2
infection [149]. Several other immunomodulators and anti-inflammatory drugs are also being applied
in clinical trials [172].
11. Public Health Announcement
Policies to reduce excessive tobacco consumption, including tobacco-free public places and the
protection of people from second-hand smoke as per Article 8 of the WHO Framework Convention
on Tobacco Control, and its guidelines, could reduce the risk of more advanced cases of COVID-19
as caused by tobacco exposure. It is important for smokers to recognize that excessive tobacco
consumption use can delay or negatively impact COVID-19 treatment and that reducing high-risk
tobacco consumption could be a method of COVID-19 prevention.
In an effort to flatten the curve and minimize the spread of this disease, it is recommended
to follow social distancing strategies, practice thorough hand washing for at least 20 s, regularly
clean highly-touched surfaces with disinfectants, wear face masks in public areas, engage in proper
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respiratory hygiene (e.g., covering coughs and sneezes), and to avoid touching the eyes, nose, or
mouth with unwashed hands [180]. The following strategies for public health could help reduce
high risk smoking during COVID-19. (1) The clinical strategies of smoking screening and counseling,
encouraged to quit, should be provided with advice, support, and pharmacotherapy; (2) Regulate
tobacco/hookah bar outlets; (3) Increase tobacco taxes and prices; (4) Enhance enforcement of laws
prohibiting sales to minors, advertising, promotion and sponsorship of tobacco/tobacco products;
(5) Stop targeting vulnerable communities by tobacco industry; and (6) Offering and encouraging for
quitting tobacco or tobacco related product consumption.
12. Research Needs
Although smoking is a well-established risk factor for the development of various respiratory
infections ranging from the common cold to more severe diseases (e.g., MERS and, SARS), there is a little
information regarding how smoking use affects COVID-19 disease progression, severity, and treatment
delivery [181]. Therefore, the most compelling and urgent research need for the nicotine and tobacco
research community should be to investigate the role of tobacco in the current COVID-19 pandemic
through the use of well-designed population-based studies that control the age and relevant risk
factors of COVID-19. International collaboration between different health organizations is necessary
to ensure that more accurate data can be identified, and analyses should focus on the role of this
association in viral contamination, illness severity, recovery rates, impact of comorbidities, and so on.
More research is needed to examine the interactions between tobacco smoke, SARS-CoV-2, ACE-2,
TMPRSS2, and their genes, including the validation of in vitro computational data and in vivo evidence.
We need data from symptomatic COVID-19 smokers to determine the immediate and the short-term
benefit of smoking cessation. Unfortunately, there are still considerable racial/ethnic disparities in
smoking susceptibility over time, and their role in COVID-19 should be explored extensively and
interventions are needed to combat this issue. Anecdotal stories from news providers about the effect
of nicotine on COVID-19 treatment are intriguing, but rigorous scientific investigations are required to
measure the effect accurately. Data on alternate delivery mechanisms for nicotine and them risk/benefit
ratio for COVID-19 are also needed. There is no direct link between identified so far between the
e-cigarettes/vaping use and risk of contracting COVID-19.
Therefore, we urgently need further research on these products and its impact on virulence
of COVID-19.
13. Conclusions
The COVID-19 pandemic has spurred a global public health crisis. The studies reviewed here
clearly indicate the complexity and multi-factorial etiology of smoking in relation to COVID-19.
Epidemiological meta-analyses findings suggest that active smoking is significantly linked with the
risk of more severity of COVID-19. Mechanistically, exposure of smoking elevated ACE-2 and activated
‘cytokine storm’ and their associated gene; this may also a possible potential therapeutic target for
SARS-CoV-2. Cessation of smoking is likely to decrease the risk of COVID-19 as well as the likelihood
of developing more severe complications. Unfortunately, health disparities still exist, as African
American and Latino/Hispanic patients have been shown to contracting SARS-CoV-2 at higher rates
and are more likely to die.
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